In the fast-paced world of pharmaceutical innovation, Bright Minds Biosciences Inc. stands at a crucial juncture as it unveils promising data on its proprietary compound, BMB-201. This mixed agonist of the 5-HT2C and 5-HT2A receptors has shown remarkable similarities in efficacy to morphine within various preclinical pain models. This breakthrough may offer a new avenue for treatment in both acute and chronic pain management without falling into the pitfalls associated with traditional opioid therapies.Opioids, particularly morphine, have long been the cornerstone of pain relief. However, the opioid crisis has underscored the urgent need for alternative therapies that can provide similar analgesic effects wi...

DRUG's Stock Performance relative to it's Customers

DRUG's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Bright Minds Biosciences Inc	124.05	0.00	-5.65	57
SUBTOTAL	0.00	0.00	0.00	-

Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com